<DOC>
	<DOCNO>NCT01286558</DOCNO>
	<brief_summary>Blood pressure hypertensive patient rarely control optimal level one drug alone , often combination two drug essential achieve sufficient antihypertensive effect . Therefore Japanese Society Hypertension ( JSH ) 2009 combination therapy recommend . In JSH 2009 advise start combination therapy low dose , increase dosage antihypertensive effect sufficient . In Japanese long-term safety study , 259 patient receive T40/A5 mg fixed-dose combination ( FDC ) , 6 week treatment 48 patient could control blood pressure ( DBP =90 ) ( U09-2494-01 ) . For patient control blood pressure T40/A5 mg FDC , switch high dose T80/A5 mg recommend . In overseas 4x4 factorial design trial , clinically meaningful difference blood pressure lower effect T80/A5 mg free combination T40/A5 mg free combination show ( U07-3503-02 ) . But sponsor data verifies difference Japanese patient . Thus , clinical trial conduct investigate antihypertensive effect safety high dose T80/A5 mg FDC compare low dose T40/A5 mg FDC Japanese patient essential hypertension . In trial , multi-centre , randomise , double-blind , double-dummy , active-controlled , parallel group comparison method employ .</brief_summary>
	<brief_title>Comparison Japan T80/A5 ( Telmisartan 80 mg Amlodipine 5 mg ) T40/A5 ( Telmisartan 40 mg Amlodipine 5 mg )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : 1 . Essential hypertensive patient If already take antihypertensive drug , mean seat diastolic blood pressure ( DBP ) must &gt; =90 &gt; =114 mmHg If take antihypertensive drug , mean seat DBP must &gt; =95 &gt; =114 mmHg 2 . Able stop current antihypertensive drug without risk patient base investigator opinion . Exclusion criterion : 1 . Patients take 3 antihypertensive drug sign informed consent form 2 . Patients know suspected secondary hypertension 3 . Patients clinically relevant cardiac arrhythmia 4 . Congestive heart failure New York Heart Association ( NYHA ) functional class IIIIV 5 . Patients recent cardiovascular event 6 . Patients history stroke transient ischaemic attack within last 6 month sign informed consent form 7 . Patients history sudden deterioration renal function angiotensin II receptor blocker ( ARBs ) angiotensin convert enzyme ( ACE ) inhibitor ; patient postrenal transplant postnephrectomy 8 . Patients previously experience characteristic symptom angioedema ( facial , tongue , pharyngeal , laryngeal swell dyspnea ) treatment ARBs ACE inhibitor 9 . Patients know hypersensitivity component investigational product , know hypersensitivity dihydropyridinederived drug 10 . Patients hepatic and/or renal dysfunction 11 . Premenopausal woman nurse pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>